




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 38/18, 48/00 // (A61K 38/18, 38:22)		(11) International Publication Number: WO 98/22128
A1		(43) International Publication Date: 28 May 1998 (28.05.98)
(21) International Application Number: PCT/IT97/00283		(74) Agents: DI CERBO, Mario et al.; Società Italiana Brevetti S.p.A., Piazza di Pietra, 39, I-00186 Roma (IT).
(22) International Filing Date: 18 November 1997 (18.11.97)		(81) Designated States: AU, CA, CN, IL, JP, KR, MX, US, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).
(30) Priority Data: RM96A000790 19 November 1996 (19.11.96) IT		Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.
(71) Applicant (for all designated States except US): ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. [IT/IT]; Via Pontina Km. 30.600, I-00040 Pomezia (IT).		
(72) Inventors; and (75) Inventors/Applicants (for US only): CILIBERTO, Gennaro [IT/IT]; Viale Colli Portuensi, 242, Pal. 6, I-00151 Rome (IT). COSTA, Patrizia [IT/IT]; Via S. Martino ai Monti, 60, I-00184 Rome (IT). PAONESSA, Giacomo [IT/IT]; Via Sofocle, 65, I-00125 Rome (IT). LAZZARO, Domenico [IT/IT]; Via Attilio Friggeri, 146, I-00136 Rome (IT). GLOAGUEN, Isabelle [FR/IT]; Via Lamarmora, 54, I-00040 Pomezia (IT). DI MARCO, Annalise [IT/IT]; Via Ugo Foscolo, 5, I-02100 Rieti (IT). DE MARTIS, Anna [IT/IT]; Via Leopoldo Ruspoli, 64, I-00149 Rome (IT). LAUFER, Ralph [AT/IT]; Via Montagne Rocciose, 68, I-00144 Rome (IT). CORTESE, Riccardo [IT/IT]; Via Massimiliano Massimo, 16, I-00144 Rome (IT).		

(54) Title: USE OF CNTF (CILIARY NEUROTROPHIC FACTOR) RECEPTOR ACTIVATORS FOR THE TREATMENT OF OBESITY

(57) Abstract

The present invention refers to the use of hCNTF (human ciliary neurotrophic factor), mutants thereof or other molecules that activate the CNTF receptor, for the preparation of drugs for the treatment of obesity and associated diseases, for example hyperglycemia. Figure 1 shows the anti-obesity effect of hCNTF and leptin on body weight (left panels) and on food intake (right panels) in genetically obese mice and in mice with diet-induced obesity (DIO).



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

USE OF CNTF (CILIARY NEUROTROPHIC FACTOR) RECEPTOR ACTIVATORS FOR THE TREATMENT OF OBESITY

5

DESCRIPTION

10

The subject of the present invention is the use of molecules that activate the CNTF (ciliary neurotrophic factor) receptor- such as hCNTF (human CNTF) or mutants of hCNTF - as active principles in the formulation of pharmaceutical compositions suitable for the treatment of obesity and of related diseases. The term hCNTF mutant is intended to mean an amino acid sequence that can in theory be derived from hCNTF by substitution of one or more amino acids.

15

20

Obesity, which affects >30% of the adult population in the industrial world, is a major public health problem, since it is associated with type II diabetes, hypertension, hyperlipidemia and increased mortality rate. Obesity is the result of a positive energy balance, as a consequence of an increased ratio of caloric intake to energy expenditure. Treatment is generally unsuccessful due to the operation of mechanisms that restore adipose mass after both intentional or unintentional changes (1). The lipostasis theory postulates that the size of the body fat depot is regulated by a feedback loop, constituted by adipocyte-derived circulating molecules that act on the hypothalamus to decrease appetite and increase energy expenditure (2).

25

30

35

The recently identified 16-kilodalton plasma protein leptin (3) fulfills many of the criteria expected from such a lipostatic hormone. It is expressed in adipose tissue, and its plasma levels are highly correlated with body mass index in rodents and humans (4). The absence of leptin in obese (*ob/ob*) mutant mice leads to a massive increase in body fat, which can be reversed by systemic administration of the recombinant protein (5, 6, 7).

However, human obesity does not appear to be due to deficient expression of leptin, since leptin mRNA and plasma protein levels were shown to be increased in obese versus lean subjects (4). Thus, obese humans may be insensitive to the lipostatic effect of leptin, possibly due to a defect at the level of leptin transport, leptin receptor activity, or post-receptorial signalling mechanisms (8).

There is thus a need in this specific field for new pharmacological agents capable of correcting obesity in people who are resistant to leptin.

Leptin resistance is a characteristic feature of the diabetic (*db/db*) mouse mutant, which expresses a truncated form of the leptin receptor lacking most of the intracytoplasmic domain (9). An animal model that more closely resembles human obesity is that of mice rendered obese by feeding a high-fat diet (DIO mice). Similar to human obese subjects, DIO mice have elevated plasma levels of leptin (4), suggesting that they are relatively insensitive to the weight-reducing effects of the hormone.

The present invention provides biologically active anti-obesity agents that can reverse obesity, as well as hyperglycemia and hyperinsulinemia associated therewith.

The subject of the present invention is therefore the use of substances that activate the CNTF receptor for the preparation of drugs for treatment of obesity and related diseases. These substances can be hCNTF (human ciliary neurotrophic factor; SEQ ID NO: 1) itself or mutants thereof (see for instance SEQ ID NOS: 2 to 28). Good results have been obtained using the hCNTF mutant (Ser166Asp/Gln167His) hCNTF (10), which, from position 159 to position 178, has the following amino acid sequence (shown as SEQ ID NO: 5 in the annexed sequence listing):

Leu Lys Val Leu Gln Glu Leu Asp His Trp Thr Val Arg
Ser Ile His Asp Leu Arg Phe [for sake of simplicity, this

hCNTF mutant will be referred to hereinafter also as DH-CNTF]. For sake of simplicity, in the annexed sequence listing, it has been indicated only the portion from position 159 to position 178 of the mutants SEQ ID NOS: 2 to 22.

A further subject of the invention is the use of DNA coding for hCNTF or mutants thereof for the preparation of compositions for the treatment of obesity and diseases related thereto.

The present invention also has as its subject a drug for the treatment of obesity and the reduction of body weight, containing, as at least one of its active principles, hCNTF or a mutant thereof, and comprising a pharmaceutically acceptable vehicle. A pharmaceutically acceptable vehicle is intended to be a vehicle that is not dangerous for the patient, that does not degrade or deactivate the active principles or that does not interfere with the effects thereof. The preferred vehicle is a physiological saline solution, but other pharmaceutically acceptable vehicles can be used, and will easily be identified by those skilled in the art. In an embodiment that has shown good results hCNTF or mutants thereof can be used in combination with leptin: in this case the ratio wild type or mutant CNTF/leptin can be selected in the range 1:500 to 1:5, preferably 1:100 to 1:25.

hCNTF or hCNTF variants can be administered to patients in need of treatment in doses ranging from about 1 to 10,000 $\mu\text{g/kg}$ body weight. A preferred dose is between 10 and 1000 $\mu\text{g/kg}$ body weight. A typical daily dose for an adult is between 1 and 100 mg. The necessary amount of active principle according to the invention can be administered in a single daily dose or in multiple doses throughout the day. The treatment regime can require administration for prolonged periods. The size of the dose administered must be determined by a physician and will depend on a number of factors, such as the

nature and gravity of the disease, the age and state of health of the patient and the patient's tolerance to the drug itself.

In a specific embodiment, hCNTF or a mutant thereof
5 can be used for treatment of obese patients by means of a short-term (1-2 weeks) daily administration, in order to obtain a rapid, significant decrease in body weight (5-10%), which can be maintained subsequently using an appropriate diet and/or physical exercise.

10 The active protein molecules can be formulated for parenteral, nasal, bronchial or transdermal administration. The pharmaceutical composition according to the present invention is preferably administered parenterally by means of an injection. In the preferred
15 embodiment, parenteral administration is subcutaneous or intramuscular. Other effective methods of administration are intravenous injections, slow-release parenteral formulations, inhalant mists, or suppositories. In the slow-release formulation the primary solvent can be
20 either of an aqueous or of a non-aqueous type. Furthermore, the vehicle can contain other pharmacologically acceptable excipients to maintain or modify the pH, viscosity, clarity, colour, sterility, stability, speed of dissolution or odor of the
25 formulation. Similarly, the vehicle can also contain other pharmacologically acceptable excipients to modify or maintain the stability, speed of dissolution, release, or absorption of the active principle. These excipients are substances that are normally used to formulate doses
30 for parenteral administration, both in the form of single doses and in the form of multiple doses.

As mentioned above, the preferred parenteral form of administration of the formulation according to the invention is subcutaneous or intramuscular. The most
35 preferred form of parenteral administration is subcutaneous. To obtain the required daily dose of active principle, it is possible to resort to single or repeated

subcutaneous or intramuscular injections. In a preferred embodiment of the invention, the dose of active principle is between 10 and 1000 $\mu\text{g/kg/day}$. For the treatment of obesity, it may be desirable to administer the active principle periodically. Periodic administration may take the form of monthly, bi-weekly, weekly, daily or hourly administration. The required frequency of administration will be apparent to those treating the patient on the basis of standard observational techniques.

It is also possible to consider oral administration of the pharmaceutical formulations according to the invention. In this case, the active principle administered is preferably encapsulated. The encapsulated active principle can be formulated with or without the vehicles usually employed in the preparation of solid doses. Preferably, the capsule is made in such a way that the active portion of the formulation is released in the gastro-intestinal tract when bioavailability is maximized and pre-systemic degradation is minimized. The formulation can also include further excipients with the aim of facilitating absorption of the active principle. It is also possible to use diluting agents, flavouring, low melting-point waxes, vegetable oils, lubricants, suspending agents, capsule disintegration agents and binding agents.

Independently of the method of administration, the specific dose is calculated according to the approximate body weight of the patient. Further refinement of the calculations necessary to determine the appropriate dose for treatment is routinely made by those of ordinary skill in the art, who are capable of reaching these results without the need for undue experimentation, especially in the light of the tests and dosing information provided herein.

According to the present invention, an obese patient is administered a therapeutically effective amount of active principle. As mentioned above, the dose required

can be determined by those skilled in the art without the need for undue experimentation. A "therapeutically effective amount" can be defined as the amount of active principle that is sufficient to cause an adequate loss of weight and to result in the consequent normalisation of metabolic parameters, such as the blood glucose level of the obese patient.

Up to this point a general description has been given of the present invention. With the aid of the following examples, a more detailed description will now be provided, with reference to specific embodiments, aimed at giving a better understanding of the aims, characteristics, advantages and operating methods of the invention. However, the scope of the present invention is not intended to be limited thereby.

DESCRIPTION OF THE FIGURES

Figure 1

Effects of hCNTF and leptin on body weight (left panels) and food intake (right panels) in genetically obese mice (*ob/ob* and *db/db*) and mice with diet-induced obesity (DIO). Mice received daily intraperitoneal injections of either vehicle or proteins (amounts in $\mu\text{g}/\text{mouse}$), starting at day 0. Body weight is expressed as percent of the original weight on day -2 and represents the average \pm s.e.m ($n = 3$ for *ob/ob* and *db/db*, $n = 5$ for DIO mice). Baseline weights for each group of vehicle-treated animals were (in grams): *ob/ob*, 49.3 ± 0.3 ; *db/db*, 39.1 ± 2.5 ; DIO, 42.6 ± 0.8 . Statistical significance was determined by repeated measures ANOVA. For all groups, P -values for the effects of treatment, time, and time \times treatment were: $P < 0.05$, $P < 0.0001$ and $P < 0.01$, respectively.

Figure 2

Effects of hCNTF (2 $\mu\text{g}/\text{mouse}$) and leptin (100 $\mu\text{g}/\text{mouse}$), administered alone or in combination, on weight loss in DIO mice. Mice received daily intraperitoneal injections of the indicated agents.

Figure 3

Duration of DH-CNTF effects on body weight and food intake in obese vs. lean mice. C57BL/KS *db/db* mice (circles), or age-and sex-matched C57BL/KS *+/+* mice (squares), housed in groups of five, received daily intraperitoneal injections of either vehicle (empty symbols) or 10 µg of DH-CNTF (filled symbols) for 25 days. From day 26, all mice were treated with vehicle. Food intake is the number of grams consumed per group divided by five.

Figure 4

Effects of DH-CNTF treatment of obese mice on carcass composition. Mice were treated for 10 days by daily intraperitoneal injections of either vehicle or 10 µg of DH-CNTF. Results are the mean ± s.e.m. (n = 5). *P < 0.05; ** P < 0.01 vs. vehicle by Student's t-test.

Figure 5

Effects of leptin and hCNTF on STAT factor activation in neuronal cell lines. GT-1-7 and SN-56 cells transfected with an expression vector for human OB-Rb were incubated for 10 min in the presence or absence of the indicated cytokines (at 100 ng/ml). Activation of cellular STAT factors was determined by electromobility shift assay. Arrows denote the positions of migration of bound STAT3 homodimers, STAT1:STAT3 heterodimers, and STAT1 homodimers.

Figure 6

Expression of receptor subunits for leptin (OB-Rb) and CNTF (CNTF receptor-α [CNTFRα] and LIFR) in mouse hypothalamus, as determined by in situ hybridisation. A, arcuate nucleus; P, paraventricular nucleus. (X100)

Figure 7

Effects of leptin and hCNTF on *tis-11* expression in mouse hypothalamus. Groups of three *ob/ob* mice received intraperitoneal injections of either vehicle, leptin (100 µg) or DH-hCNTF (10 µg) and were sacrificed one hour later by cervical dislocation. In situ hybridization was

performed on frozen coronal brain sections from vehicle- or protein-treated mice, using ^{35}S -labelled cRNA probes specific for murine *tis-11*. (x 100).

EXAMPLE 1

Anti-obesity effects of hCNTF and its mutant DH-CNTF Methods

Protein production. Recombinant human CNTF and DH-CNTF were produced in *E. coli* BL21 as previously described (11). The DNA coding sequence for human leptin was assembled by PCR using synthetic oligodeoxyribonucleotides according to the method of Stemmer et al. (12), and subcloned into the bacterial expression plasmid pRSET-5d (13). Human leptin was produced using the same protocol as for hCNTF. All proteins were purified by reverse-phase HPLC (11) in order to remove bacterial lipopolysaccharide. Purified preparations contained less than 5 ng endotoxin/mg protein, as determined by the Limulus amoebocyte assay (Sigma).

Animal studies. Experiments were performed using groups of male 10-11 week-old C57BL/6J *ob/ob* and C57BL/KS *db/db* mice, and 19 week-old AKR/J mice rendered obese by feeding a high-fat diet (14) starting at 12 weeks of age. Except where noted otherwise, animals were housed in individual cages with *ad libitum* access to water and either standard or high-fat (AKR mice) rodent chow, under a 12 hour light-dark cycle (lights on at 7:30 hr, off at 19:30 hr). They were accustomed to daily (9:00 hr) intraperitoneal injections of vehicle (0.9% saline, 0.2 mg/ml endotoxin-free bovine serum albumin) for two days before the beginning of the treatment (day 0) with either vehicle or cytokines. Animals were weighed after injection and food intake was determined by recording the amount of chow remaining in food dishes.

Results

Human ciliary neurotrophic factor (hCNTF), its mutant DH-CNTF (10) [(Ser166Asp/Gln167His) hCNTF]; a

mutant of hCNTF with 40-fold higher affinity for the CNTF
a-receptor) and human leptin were tested for biological
activity in genetically obese mice, and in mice with
diet-induced obesity (DIO). These models of obesity and
5 diabetes are generally accepted in the art as indicative
of the obese condition. Agents showing an anti-obesity
effect in these models will show a similar effect in
other mammals, in particular in man.

As will be seen more clearly in the following, the
10 compounds of the invention are active in all the
biological tests mentioned above, and are also found to
be anti-obesity agents. Furthermore, they are active in
reversing the hyperglycemia and hyperinsulinemia
associated with obesity. It is therefore assumed that
15 these compounds will also be of use in the treatment of
hyperglycemia in human diabetes mellitus.

In accordance with previous experiments and results
(6-8, 15), it was found that systematic administration of
leptin to mutant *ob/ob* mice, which do not express
20 functional leptin, reverses the obesity and the
hyperphagia associated with leptin deficiency. Daily
intraperitoneal administration of hCNTF (between 2 and 50
 $\mu\text{g}/\text{mouse}$; corresponding to 40-1000 $\mu\text{g}/\text{kg}$ body weight) to
ob/ob mice also produces a progressive and dose-dependent
25 decrease in body weight, as well as a rapid reduction in
food intake (Fig. 1). At the highest dose tested (50 μg ;
1000 $\mu\text{g}/\text{kg}$), hCNTF causes a 16% decrease in body weight
after 7 days (compared with a 5% increase in vehicle-
treated controls), and a 5-fold decrease in food intake.
30 These effects are comparable in magnitude to those of a
100 μg (2000 $\mu\text{g}/\text{kg}$) dose of leptin (13% and 95%
reductions in body weight and food intake, respectively;
 $p < 0.0001$ by Student's *t*-test). The hCNTF variant DH-CNTF
produces similar reductions in body weight and food
35 intake at doses approximately 5 times lower than those of
hCNTF. This result, together with the lack of activity of
hCNTF variants (11) with impaired receptor interaction

(data not shown), suggests that the anti-obesity effect of hCNTF is mediated through activation of specific CNTF receptors.

The *db/db* mutant mouse does not respond to leptin (6-8, 15), because of a mutation in the gene coding for the leptin receptor OB-R, which results in the production of a receptor splice variant with a truncated intracytoplasmic domain (9, 29). In contrast, treatment of *db/db* mice with hCNTF causes a dose- and time-dependent weight loss and suppression of food intake (Fig. 1). The superagonist DH-CNTF elicited comparable effects at approximately 1/5 the dose of hCNTF. The results obtained in *ob/ob* and *db/db* mice show that hCNTF does not act by stimulating the release of leptin or by direct activation of leptin receptors.

AKR mice rendered obese by feeding a high-fat diet (DIO mice) have been previously reported to be less sensitive than *ob/ob* mice to the weight- and appetite-reducing effects of leptin (7). This finding, together with the observation that plasma levels of leptin are higher in DIO mice than in lean littermates, led to the proposal that diet-induced obesity is associated with leptin resistance (4, 17). As shown in Fig. 1, a 5-day treatment of DIO mice with human leptin (100 µg; 2500 µg/kg) causes modest decreases in body weight ($7 \pm 1\%$; $p < 0.05$ vs. vehicle) and food intake ($27 \pm 2\%$; $p < 0.05$). In contrast, hCNTF (50 µg; 1250 µg/kg) and DH-CNTF (10 µg; 250 µg/kg) elicit more extensive reductions in body weight ($19 \pm 1\%$ and $24 \pm 1\%$, respectively; $p < 0.0001$) and food intake ($76 \pm 4\%$, and $73 \pm 7\%$, respectively; $p < 0.0005$). The discovery that hCNTF can reverse obesity in both *db/db* and DIO mice has important implications for the treatment of human obesity, which has been postulated to be associated with resistance to leptin (4, 18, 19).

As can be seen, the obese mice received daily intraperitoneal administrations of hCNTF or of the mutant DH-CNTF in doses of from 2 to 50 µg, corresponding to 50-

1000 µg/kg body weight. At the highest dose, the compounds cause a reduction of over 10% in the body weight after 5 days of treatment. Therefore, doses of hCNTF or DH-CNTF of under 1000 µg/kg are administered to patients suffering from obesity; preferably doses of approximately 100 µg/kg, in order to induce a rapid reduction in body weight (5-10%). Furthermore, in this form of preferred embodiment, hCNTF or DH-CNTF is administered once a day and the treatment is continued for a few days, until the required reduction in body weight is obtained.

EXAMPLE 2

Increase in the anti-obesity effect of leptin due to synergism with hCNTF in DIO mice

Obese DIO mice were given daily intraperitoneal injections of leptin (100 µg; corresponding to 2500 µg/kg) along with a small dose (2 µg, corresponding to 50 µg/kg) of hCNTF. Neither of the two agents produces a significant weight loss per se. This treatment has the effect of producing a strong, synergistic loss of body weight (Fig. 2). This result proves that small doses of hCNTF can be used to give a significant increase in the effect of leptin in a model of obesity associated with a resistance to leptin.

EXAMPLE 3

Duration and specificity of the anti-obesity effects of DH-CNTF

Methods

Behavioral studies. Locomotor activity was measured by scoring the number of times mice crossed the middle of their home cages during three hours of the dark cycle (21:00 hr-24:00 hr). Grooming behavior was assessed by focal observations in home cages (five observations of 1 min each during 30 min of the light cycle), using a rating scale from 0 to 3 (0, no activity; 1, weak; 2, normal; 3 hyperactive). Conditioned taste aversion was performed using a two-bottle paradigm with 0.1% saccharin

as a novel taste (20).

Body composition. Carcasses were homogenized, and 2-gram aliquots were lyophilized and then oven-dried at 90° until weight was constant. Fat was then extracted with ethyl ether/ethanol (20:1, v/v) (21). Water and fat mass were calculated from the weight differences after dehydration and fat extraction, respectively. Lean mass was defined as the remaining amount of carcass.

Results

hCNTF has previously been reported to cause a transient reduction of body weight and food intake in normal mice (22). Its effects on obese animals have not been studied heretofore. It is therefore important to determine whether or not its effects on obese mice are subject to desensitisation. As shown in Fig. 3, DH-hCNTF produces protracted effects in obese mice. A 25-day treatment of *db/db* mice with DH-CNTF leads to a progressive and steady decrease in body weight, which by day 8 reaches a level corresponding to that of age- and sex-matched wild-type mice. In parallel, DH-CNTF elicits a ~50% decrease in food intake, which persists throughout the treatment. Similar results were obtained in *ob/ob* mice treated for 17 days with hCNTF (data not shown). In contrast, DH-CNTF elicits only transient effects in strain-matched wild-type mice. Thus, DH-CNTF rapidly depresses both food intake and the rate of body weight change in lean mice, but these effects subside after approximately 5 and 10 days of treatment, respectively (Fig. 3).

A possible explanation for the observed differences between obese and lean animals is that hCNTF, similarly to leptin (5,6), predominantly depletes adipose tissue mass, such that the extent and duration of its effect would depend on the size of fat depots. Indeed, DH-CNTF specifically reduces the percentage of body fat in *ob/ob* and *db/db* mice, while increasing that of body water and lean mass as compared with vehicle-treated controls (Fig.

4). The absolute weight loss induced by DH-CNTF can be accounted for by a predominant loss of body fat (60-70% of lost mass), accompanied by a smaller reduction in water mass (see absolute weights in Fig. 4). Leptin produces similar effects in *ob/ob* mice (5,6). Thus, in obese mice, hCNTF elicits specific anti-adiposity effects. In contrast, hCNTF has been reported to cause reductions in muscle (23) or protein (24) mass in lean animals. A plausible explanation for this apparent discrepancy is that the predominant fat-depleting effect of hCNTF leads to a nearly total loss of body fat in lean animals (ref. (23) and our unpublished results), which causes protein loss as a secondary event.

hCNTF does not induce toxicity, malaise or illness. Irreversible toxicity was ruled out by the finding that body weight and food intake rapidly return to pretreatment levels following interruption of protein administration, both in *db/db* (Fig. 2G, H) and *ob/ob* mice (data not shown). Locomotor activity is not significantly altered by a 3-day treatment of *db/db* mice with DH-CNTF (10 µg) as compared to vehicle-treated controls (activity scores: 43 ± 6 and 49 ± 6 , respectively; $n=5$). Likewise, DH-CNTF treatment does not alter grooming behavior (activity scores: 1.2 ± 0.6 and 1.0 ± 0.4 , for DH-CNTF and vehicle-treated, respectively). In addition, DH-CNTF does not induce any form of stereotypic behavior. The possibility that the protein causes taste aversion was examined in DIO mice using a two-bottle paradigm with 0.1% saccharin as a novel taste (20). Similarly to leptin, which was reported to reduce water intake in *ob/ob* mice (5), DH-CNTF (10 µg) causes a decrease in water intake of DIO mice 2 days after conditioning (1.8 ± 0.1 ml vs. 2.8 ± 0.2 ml in vehicle-treated controls; $n = 9$; $P < 0.001$). However, DH-CNTF does not cause taste aversion (saccharin intake $49 \pm 2\%$ of total fluid vs. $51 \pm 4\%$ in controls). These results indicate that the

satiety effect of DH-CNTF is not due to cytokine-induced sickness behavior.

EXAMPLE 4

Reversal of obesity-associated metabolic defects by hCNTF and DH-CNTF

Methods

Mice received daily intraperitoneal injections of either vehicle, leptin (100 µg), hCNTF (50 µg) or DH-CNTF (10 µg). In pair-feeding experiments (2 and 4), vehicle-treated mice were either fed *ad libitum* (control) or fed the same amount of chow consumed by DH-CNTF-treated mice during the preceding 24-hour period. Blood samples were taken 24 hours after the last injection (experiments 1 and 3), or 7 hours after the last injection and the removal of food (experiments 2 and 4). Serum glucose was determined by the glucose oxidase method and serum insulin by radioimmunoassay (Amersham), using rat insulin as standard.

Results

In addition to its weight- and appetite-regulating actions, hCNTF and DH-CNTF are able to reverse the hyperglycemia and hyperinsulinemia associated with the *ob* and *db* mutations.

Mice bearing the *ob* mutation on the C57BL/6 background exhibit strong hyperinsulinemia (with nearly normal glucose levels after the age of 2-3 months) (25), which can be corrected by leptin treatment (5,6,15). Treatment of *ob/ob* mice with hCNTF or DH-CNTF also lead to strong reductions in serum insulin levels (Table 1, experiments 1 and 2). The *db/db* mutant on the C57BL/KS background is characterized by severe hyperglycemia (with nearly normal insulin levels after the age of 2-3 months) (26). As previously reported (5,6,15), leptin is unable to reverse hyperglycemia in *db/db* mice. In contrast, hCNTF and DH-hCNTF lead to 2-3-fold reductions in both fed and fasted serum glucose levels, without affecting the already low levels of insulin (Table 1, experiments 3

and 4). The weight-reducing and anti-diabetic effects of DH-CNTF exceed those induced by pair-feeding of *ob/ob* or *db/db* mice to the food intake of cytokine-treated animals (Table 1, experiments 2 and 4). These results show that
5 the effects of hCNTF, similarly to those of leptin (6, 27, 28) are not solely due to decreased food intake.

Table 1

Effects of leptin, hCNTF and pair-feeding on body weight change and serum insulin and glucose in obese mice

	Treatment	Weight change (g)	Serum glucose (mM)	Serum insulin (ng/ml)
5	Experiment 1 (ob/ob, 7 days)			
	Vehicle	+1.6 ± 0.1	nd	63.3 ± 12.7
	Leptin	-6.5 ± 0.4**	nd	8.1 ± 9.1*
	hCNTF	-8.2 ± 0.1**	nd	4.3 ± 1.0*
10	DH-CNTF	-7.7 ± 0.8**	nd	3.2 ± 2.9*
	Experiment 2 (ob/ob, 4 days)			
	Vehicle	+0.5 ± 0.5	nd	72.5 ± 25.7
15	DH-CNTF	-8.4 ± 0.5**§	nd	8.1 ± 0.2*†
	Pair-fed	-7.0 ± 0.5**	nd	11.1 ± 0.4*
	Experiment 3 (db/db, 7 days)			
20	Vehicle	+0.2 ± 0.4	23.3 ± 0.8	9.1 ± 4.2
	Leptin	-0.8 ± 0.5	28.7 ± 0.8*	9.7 ± 2.6
	hCNTF	-6.8 ± 0.5**	8.4 ± 1.7**	8.2 ± 2.1
	Experiment 4 (db/db, 4 days)			
25	Vehicle	0.0 ± 0.3	30.1 ± 2.0	nd
	DH-CNTF	-6.8 ± 0.4**§	12.3 ± 1.9**§	nd
	Pair-fed	-5.3 ± 0.4**	24.8 ± 5.4	nd

Data are mean values ± s.e.m. from 3-6 animals per treatment group. nd, not determined. *P < 0.05 vs. vehicle **P < 0.001 vs. vehicle §P < 0.05 vs. pair-fed †P < 0.001 vs. pair-fed (Student's t-test).

EXAMPLE 5hCNTF and leptin activate overlapping neuronal signaling systemsMethods

5 STAT activation assay. GT-1-7 and SN-56 cells were maintained in complete culture medium (Dulbecco's modified Eagle medium containing 10% fetal calf serum, penicillin, glutamine and, for SN-56 cells, sodium pyruvate). Cells were plated in 100 mm dishes and used 24
10 hours later, when semi-confluent. An expression vector containing the entire coding region (nucleotides 141-3770) of human OB-R (29) was prepared as previously described (30) and was transfected into the cells by Lipofectamine (Gibco BRL) according to the manufacturer's
15 instructions. After 24 hours, cells were distributed into 60 mm culture dishes containing complete culture medium, and after an additional 24 hours, they were deprived of serum for 4 hours before a 10 min treatment with different effectors, as specified below. The cells were
20 then washed with ice-cold phosphate-buffered saline containing 50 mM NaF, collected by centrifugation and frozen in liquid nitrogen. Total cell extracts were prepared as previously described (31). Binding of activated STAT factors to the high affinity SIE m67
25 oligonucleotide (32) was determined by electromobility shift assays according to Sadowsky and Gilman (33), using 10 µg of cell extract. The oligonucleotide probe was labelled by filling in 5' protruding ends with Klenow enzyme in the presence of [α-³²P]dATP and [α-³²P]dCTP
30 (3000 Ci/mmol). Complexes were resolved on 5% polyacrylamide/2.5% glycerol/0.5X TBE (45 mM Tris-borate, 0.5 mM EDTA, pH 7.8) gels, which were then dried and subjected to autoradiography.

35 In situ hybridization. Serial coronal brain sections were prepared in the region containing the arcuate and paraventricular hypothalamic nuclei. In situ hybridization was performed according to previously

described procedures (34), using ³⁵S-labelled cRNA probes. Specific probes for murine OB-Rb, CNTFRα, LIFR and *tis-11* were obtained by RT-PCR amplification of mouse brain RNA using appropriate oligonucleotide primers, and corresponded to nucleotides 2850-3407, 246-856 (numbering according to the human sequence) 2620-3217, and 1-950 of the respective coding sequences.

Results

The partially shared biological activities of hCNTF and leptin suggest that these proteins act through similar signaling mechanisms. The ability of hCNTF and leptin to regulate the DNA binding activity of STAT transcription factors was examined in two neuronal cell lines, SN-56 (35) and GT-1-7 (36), derived from mouse septal and hypothalamic neurons, respectively. Cells were transfected with an expression vector for human OB-Rb, the signaling-competent long-form splice variant of OB-R (30, 37, 38). In both neuronal cell lines, hCNTF and leptin trigger the activation of a similar pattern of STAT factors, with predominant DNA binding of STAT3 homodimers and, to a lesser degree, that of STAT1 homodimers and STAT1/STAT3 heterodimers. (Fig. 5). This pattern is characteristic of gp130-signaling cytokines (39), consistent with the sequence similarity, including the presence of consensus motifs for JAK kinase and STAT factor interaction sites, between OB-Rb and receptors of the gp130 family (9).

A possible explanation for the overlapping metabolic effects of leptin and hCNTF is that these proteins stimulate common effector pathways in brain areas involved in the regulation of energy intake and expenditure. The long-form OB-Rb splice variant, is predominantly expressed in such regions, including the arcuate, ventromedial and paraventricular hypothalamic nuclei (40,41). To determine whether hypothalamic satiety centers could also be targets for hCNTF, *in situ* hybridization was performed using cRNA probes specific

for murine OB-Rb, CNTFR α and LIFR. As shown in Fig. 6, the arcuate and paraventricular nuclei of the mouse hypothalamus express mRNAs for leptin and CNTF receptor subunits. Preliminary results indicate expression of CNTFR α and LIFR in additional nuclei, including the ventromedial hypothalamus.

In agreement with the existence of a cytokine signaling pathway to central satiety centers, systemically administered leptin activates early signaling responses in mouse hypothalamus (42, 43). If the mechanism of action of hCNTF is similar to that of leptin, early activation of hypothalamic responses should be detectable also after peripheral administration of hCNTF. The *tis-11* primary response gene (44), which is rapidly induced by hCNTF and other Stat3-dependent cytokines (45) was used as a marker for cellular activation. Hypothalamic *tis-11* mRNA of *ob/ob* mice was found to be significantly elevated one hour after intraperitoneal injection of leptin or DH-CNTF as compared to vehicle-treated controls. *In situ* hybridization revealed that the arcuate nucleus is a major site of *tis-11* induction by both cytokines (Fig. 7).

This result demonstrates that systemically administered hCNTF and leptin can induce early signaling responses in a brain region that has been implicated as an important target of leptin action (15, 41). It cannot be excluded that the cytokines activate hypothalamic cells indirectly, for instance through peripheral mediators or via afferent nerves. Yet, the rapidity of this effect, together with the expression of specific receptors for hCNTF and leptin in the arcuate nucleus argue for a direct action consequent to cytokine entry into the hypothalamus. Both hCNTF (46) and leptin (47) can cross the blood-brain barrier. Cytokines may penetrate into the brain via specific transport systems, as reported for leptin (47). They may also gain access to

hypothalamic neurons through circumventricular organs lying outside the blood-brain barrier, such as the median eminence, which is adjacent to the arcuate nucleus (48). In conclusion, the present results are consistent with the notion that the partially shared biological activities of hCNTF and leptin involve a related mechanism of action.

EXAMPLE 6

CNTFR α binding activities of hCNTF and hCNTF variants

The relative binding affinities to CNTF receptor- α (CNTFR α) of hCNTF and different hCNTF variants were determined by solid phase binding assay as previously described (10). As shown in Table 2, a number of hCNTF variants possessed greater affinity for CNTFR α than wild-type hCNTF. These variants, like DH-CNTF, have increased utility for treatment of obesity and associated diseases, such as diabetes.

- 21 -

Table 2. CNTF receptor α binding of hCNTF and hCNTF variants

SEQ ID Name NO:	Abbrevn. /note	Relative Binding (hCNTF =1)
1	hCNTF	wild type 1.1 \pm 0.3
2	(Gln167Thr) hCNTF	11.8 \pm 0.3
3	(Lys160Gln/Gln167Thr) hCNTF	3.1 \pm 1.0
4	(Gln167Tyr) hCNTF	9.6 \pm 2.6
5	(Ser166Asp/Gln167His) hCNTF	22.8 \pm 3.5
6	(Gln163Ser/Gln167His) hCNTF	4.1 \pm 1.1
7	(Gln167Ala) hCNTF	9.0 \pm 0.7
8	(Ser166Ala/Gln167Ala) hCNTF	8.1 \pm 2.8
9	(Ser166Gly/Gln167Ala) hCNTF	7.5 \pm 2.2
10	(Ser166Asn/Gln167Ala) hCNTF	12.4 \pm 1.2
11	(Ser166His/Gln167Ala) hCNTF	8.8 \pm 2.6
12	(Ser166Asp/Gln167Ala) hCNTF	13.5 \pm 1.7
13	(Val161Leu/Gln167Ala) hCNTF	8.8 \pm 0.4
14	(Lys160Gln/Gln167Ala) hCNTF	11.7 \pm 3.2
15	(Gln167Ala/His174Ala) hCNTF	3.6 \pm 0.8
16	(Gln167Ala/Arg177Leu) hCNTF	11.7 \pm 3.3
17	(Gln167Ala/Thr169Ser) hCNTF	6.9 \pm 1.3
18	(Gln167Ala/Thr169Leu) hCNTF	9.6 \pm 2.2
19	(Gln167Ala/Thr169Leu/Phe178Ile) hC	8.4 \pm 0.4
20	(Ser166Asp/Gln167Ala/Thr169Leu) hC	21.0 \pm 1.6
21	(Ser166Asp/Gln167Ala/Arg177Phe) hC	13.1 \pm 2.0
22	(Val170Arg/His174Ala) hCNTF	3.3 \pm 0.4

5

10

15

20

- 22 -

SEQ ID Name NO:	Abbrevn. /note	Relative Binding (hCNTF =1)
23	(Phe152Ala/Ser166Asp/Gln167His) hC	32 ± 11
24	(Lys155Ala/Ser166Asp/Gln167His) hC	51 ± 19
25	(Gln63Arg) hCNTF	2.0 ± 0.3
26	(Gln63Arg/Ser166Asp/Gln167His) hCN	66 ± 16
27	(Asp30Gln/Ser166Asp/Gln167His) hCN	30 ± 5
28	(Thr169Ile/His174Ala) hCNTF	0.07 ± 0.01

5

10

15

20

REFERENCES

1. Weigle, D. S. (1994) *FASEB J.* 8, 302-310
2. Harris, R. B. S. (1990) *FASEB J.* 4, 3310-3318
- 5 3. Zhang, Y., Proenca, R., Maffei, M., Barone, M., Leopold, L., and Friedman, J. M. (1994) *Nature* 372, 425-431
4. Maffei, M., Halaas, J., Ravussin, E., Pratley, R. E., Lee, G. H., Zhang, Y., Fei, H., Kim, S., Lallone, R., Ranganathan, S., Kern, P. A., and Friedman, J. M. (1995)
10 *Nature Med.* 1, 1155-1161
5. Pelleymounter, M. A., Cullen, M. J., Baker, M. B., Hecht, R., Winters, D., Boone, T., and Collins, F. (1995) *Science* 269, 540-543
- 15 6. Halaas, J. L., Gajiwala, K. S., Maffei, M., Cohen, S. L., Chait, B. T., Rabinowitz, D., Lallone, R. L., Burley, S. K., and Friedman, J. M. (1995) *Science* 269, 543-546
7. Campfield, L. A., Smith, F. J., Guisez, Y., Devos, R., and Burn, P. (1995) *Science* 269, 546-549
- 20 8. Bray, G. A. (1996) *Lancet* 348, 140
9. Chen, H., Charlat, O., Tartaglia, L. A., Woolf, E. A., Weng, X., Ellis, S. J., Lakey, N. D., Culpepper, J., Moore, K. J., Breitbart, R. E., Duyk, G. M., Tepper, R. I., and Morgenstern, J. P. (1996) *Cell* 84, 491-495
- 25 10. Saggio, I., Gloaguen, I., Poiana, G., and Laufer, R. (1995) *EMBO J.* 14, 3045-3054
11. Di Marco, A., Gloaguen, I., Graziani, R., Paonessa, G., Saggio, I., Hudson, K. R., and Laufer, R. (1996) *Proc. Natl. Acad. Sci. USA* 93, 9247-9252
- 30 12. Stemmer, W. P., Cramer, A., Ha, K. D., Brennan, T. M., and Heyneker, H. L. (1995) *Gene* 164, 49-53
13. Schoepfer, R. (1993) *Gene* 124, 83-85
14. West, D. B., Boozer, C. N., Moody, D. L., and Atkinson, R. L. (1992) *Am. J. Physiol.* 262, R1025-R1032
- 35 15. Stephens, T. W., Basinski, M., Bristow, P. K., Bue-Valleskey, J. M., Burgett, S. G., Craft, L., Hale, J., Hoffmann, J., Hsiung, H. M., Kriauciunas, A., MacKellar,

- W., Rosteck, P. R. J., Schoner, B., Smith, D., Tinsley, F. C., Zhang, X. -Y., and Heiman, M. (1995) *Nature* 377, 530-532
16. Lee, G. -H., Proenca, R., Montez, J. M., Carroll, K. M., Darvishzadeh, J. G., Lee, J. I., and Friedman, J. M. (1996) *Nature* 379, 632-635
17. Frederich, R. C., Hamann, A., Anderson, S., Löllmann, B., Lowell, B. B., and Flier, J. S. (1995) *Nature Med.* 1, 1311-1314
18. Hamilton, B. S., Paglia, D., Kwan, A. Y. M., and Deitel, M. (1995) *Nature Med.* 1, 953-956
19. Considine, R. V., Sinha, M. K., Heiman, M. L., Kriauciunas, A., Stephens, T. W., Nyce, M. R., Ohannesian, J. P., Marco, C. C., McKee, L. J., Bauer, T. L., and Caro, J. F. (1996) *N. Engl. J. Med.* 334, 292-295
20. Langhans, W., Harlacher, R., Balkowski, G., and Scharrer, E. (1990) *Physiol. Behav.* 47, 805-813
21. Leshner, A. I., Litwin, V. A., and Squibb, R. L. (1972) *Physiol. Behav.* 9, 281-282
22. Fantuzzi, G., Benigni, F., Sironi, M., Conni, M., Carelli, M., Cantoni, L., Shapiro, L., Dinarello, C. A., Sipe, J. D., and Ghezzi, P. (1995) *Cytokine* 7, 150-156
23. Henderson, J. T., Seniuk, N. A., Richardson, P. M., Gauldie, J., and Roder, J. C. (1994) *J. Clin. Invest.* 93, 2632-2638
24. Espat, N. J., Auffenberg, T., Rosenberg, J. J., Rogy, M., Martin, D., Fang, C. H., Hasselgren, P. O., Copeland, E. M., and Moldawer, L. L. (1996) *Am. J. Physiol.* 271, R185-R190
25. Sprang, S. R. and Bazan, J. F. (1993) *Curr. Opin. Struct. Biol.* 3, 815-827
26. Paonessa, G., Graziani, R., De Serio, A., Savino, R., Ciapponi, L., Lahm, A., Salvati, A. L., Toniatti, C., and Ciliberto, G. (1995) *EMBO J.* 14, 1942-1951
27. Levin, N., Nelson, C., Gurney, A., Vandlen, R., and De Sauvage, F. (1996) *Proc. Natl. Acad. Sci. USA* 93, 1726-1730

28. Schwartz, M. W., Baskin, D. G., Bukowski, T. R., Kuijper, J. L., Foster, D., Lasser, G., Prunkard, D. E., Porte, D. Jr., Woods, S. C., Seeley, R. J., and Weigle, D. S. (1996) *Diabetes* 45, 531-535
- 5 29. Tartaglia, L. A., Dembski, M., Weng, X., Deng, N., Culpepper, J., Devos, R., Richards, G. J., Campfield, L. A., Clark, F. T., Deeds, J., Muir, C., Sanker, S., Moriarty, A., Moore, K. J., Smutko, J. S., Mays, G. G., Woolf, E. A., Monroe, C. A., and Tepper, R. I. (1995) *Cell* 83, 1263-1271
- 10 30. Rosenblum, C. I., Tota, M., Cully, D., Smith, T., Collum, R., Qureshi, S., Hess, J. F., Phillips, M. S., Hey, P. J., Vongs, A., Fong, T. M., Xu, L., Chen, H. Y., Smith, R. G., Schindler, C., and Van der Ploeg, L. H. T. (1996) *Endocrinology* 137, 5178-5181
- 15 31. Demartis, A., Bernassola, F., Savino, R., Melino, G., and Ciliberto, G. (1996) *Cancer Res.* 56, 4213-4218
32. Wagner, B. J., Hayes, T. E., Hoban, C. J., and Cochran, B. H. (1990) *EMBO J.* 9, 4477-4484
- 20 33. Sadowski, H. B. and Gilman, M. Z. (1993) *Nature* 362, 79-83
34. Lazzaro, D., Price, M., De Felice, M., and Di Lauro, R. (1991) *Development* 113, 1093-1104
35. Lee, H. J., Hammond, D. N., Large, T. H., and Wainer, B. H. (1990) *Dev. Brain Res.* 52, 219-228
- 25 36. Mellon, P. L., Windle, J. J., Goldsmith, P. C., Padula, C. A., Roberts, J. L., and Weiner, R. I. (1990) *Neuron* 5, 1-10
37. Ghilardi, N., Ziegler, S., Wiestner, A., Stoffel, R., Heim, M. H., and Skoda, R. C. (1996) *Proc. Natl. Acad. Sci. USA* 93, 6231-6235
- 30 38. Baumann, H., Morella, K. K., White, D. W., Dembski, M., Bailon, P. S., Kim, H., Lai, C. -F., and Tartaglia, L. A. (1996) *Proc. Natl. Acad. Sci. USA* 93, 8374-8378
- 35 39. Schindler, C. and Darnell, J. E. (1995) *Annu. Rev. Biochem.* 64, 621-651
40. Mercer, J. G., Hoggard, N., Williams, L. M.,

Lawrence, C. B., Hannah, L. T., and Trayhurn, P. (1996)
FEBS Lett. 387, 113-116

41. Schwartz, M. W., Seeley, R. J., Campfield, L. A.,
Burn, P., and Baskin, D. G. (1996) *J. Clin. Invest.* 98,
5 1101-1106

42. Woods, A. J. and Stock, M. J. (1996) *Nature* 381, 745-
740

43. Vaisse, C., Halaas, J. L., Horvath, C. M., Darnell, J.
E. Jr., Stoffel, M., and Friedman, J. M. (1996) *Nature*
10 *Gen.* 14, 95-97

44. Varnum, B. C., Ma, Q., Chi, T., Fletcher, B., and
Herschman, H. R. (1991) *Mol. Cell. Biol.* 11, 1754-1758

45. Ip, N. Y., McClain, J., Barrezueta, N. X., Aldrich,
T. H., Pan, L., Li, Y., Wiegand, S. J., Friedman, B.,
15 Davis, S., and Yancopoulos, G. D. (1993) *Neuron* 10, 89-
102

46. Poduslo, J. F. and Curran, G. L. (1996) *Mol. Brain*
Res. 36, 280-286

47. Banks, W. A., Kastin, A. J., and Gutierrez, E. G
20 (1994) *Neurosci. Lett.* 179, 53-56

48. Johnson, A. K. and Gross, P. M. (1993) *FASEB J.* 7,
678-686

SEQUENCE LISTING

GENERAL INFORMATION:

(i) APPLICANT: ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.p.A.

(ii) TITLE OF INVENTION: "USE OF SUBSTANCES THAT ACTIVATE THE CNTF (CILIARY NEUROTROPHIC FACTOR) RECEPTOR FOR THE PREPARATION OF DRUGS FOR THE TREATMENT OF OBESITY AND ASSOCIATED DISEASES"

(iii) NUMBER OF SEQUENCES: 28

(iv) MAILING ADDRESS:

- (A) ADDRESSEE: Societa' Italiana Brevetti
- (B) STREET: Piazza di Pietra, 39
- (C) CITY: Rome
- (D) COUNTRY: Italy
- (E) POST CODE: I-00186

(v) COMPUTER-READABLE FORM:

- (A) TYPE OF SUPPORT: Floppy disk 3.5'' 1.44 MBYTES
- (B) COMPUTER: IBM PC compatible
- (C) OPERATING SYSTEM: PC-DOS/MS-DOS Rev. 5.0
- (D) SOFTWARE: Microsoft Word 6.0

(viii) AGENT INFORMATION

- (A) NAME: DI CERBO Mario (Dr.)
- (B) REFERENCE: RM/X88924/PC-DC

(ix) TELECOMMUNICATIONS INFORMATION

- (A) TELEPHONE: 06/6785941
- (B) TELEFAX: 06/6794692
- (C) TELEX: 612287 ROPAT

(1) INFORMATION FOR SEQ ID. NO: 1:

(i) SEQUENCE CHARACTERISTIC:

- (A) LENGTH: 200 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: protein

(ix) FEATURE:

- (A) NAME: hCNTF wild type

(B) OTHER INFORMATION: hCNTF sequence from position 1 to position 200

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

Met	Ala	Phe	Thr	Glu	His	Ser	Pro	Leu	Thr	Pro	His	Arg	Arg	Asp
1				5					10					15
Leu	Cys	Ser	Arg	Ser	Ile	Trp	Leu	Ala	Arg	Lys	Ile	Arg	Ser	Asp
				20					25					30
Leu	Thr	Ala	Leu	Thr	Glu	Ser	Tyr	Val	Lys	His	Gln	Gly	Leu	Asn
				35					40					45
Lys	Asn	Ile	Asn	Leu	Asp	Ser	Ala	Asp	Gly	Met	Pro	Val	Ala	Ser
				50					55					60
Thr	Asp	Gln	Trp	Ser	Glu	Leu	Thr	Glu	Ala	Glu	Arg	Leu	Gln	Glu
				65					70					75
Asn	Leu	Gln	Ala	Tyr	Arg	Thr	Phe	His	Val	Leu	Leu	Ala	Arg	Leu
				80					85					90
Leu	Glu	Asp	Gln	Gln	Val	His	Phe	Thr	Pro	Thr	Glu	Gly	Asp	Phe
				95					100					105
His	Gln	Ala	Ile	His	Thr	Leu	Leu	Leu	Gln	Val	Ala	Ala	Phe	Ala
				110					115					120
Tyr	Gln	Ile	Glu	Glu	Leu	Met	Ile	Leu	Leu	Glu	Tyr	Lys	Ile	Pro
				125					130					135
Arg	Asn	Glu	Ala	Asp	Gly	Met	Pro	Ile	Asn	Val	Gly	Asp	Gly	Gly
				140					145					150
Leu	Phe	Glu	Lys	Lys	Leu	Trp	Gly	Leu	Lys	Val	Leu	Gln	Glu	Leu
				155					160					165
Ser	Gln	Trp	Thr	Val	Arg	Ser	Ile	His	Asp	Leu	Arg	Phe	Ile	Ser
				170					175					180
Ser	His	Gln	Thr	Gly	Ile	Pro	Ala	Arg	Gly	Ser	His	Tyr	Ile	Ala
				185					190					195
Asn	Asn	Lys	Lys	Met										
				200										

(2) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: unknown

- 29 -

(ii) MOLECULE TYPE: protein

(ix) FEATURE:

(A) NAME: (Gln167Thr) hCNTF

(B) OTHER INFORMATION: (Gln167Thr) hCNTF sequence
from position 159 to position 178

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

Leu Lys Val Leu Gln Glu Leu Ser Thr Trp Thr Val Arg Ser Ile

1 5 10 15

His Asp Leu Arg Phe

20

(3) INFORMATION FOR SEQ ID NO: 3:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 amino acids

(B) TIPO: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: protein

(ix) FEATURE:

(A) NAME: (Lys160Gln/Gln167Thr) hCNTF

(B) OTHER INFORMATION: (Lys160Gln/Gln167Thr) hCNTF
sequence from position 159 to position 178

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

Leu Gln Val Leu Gln Glu Leu Ser Thr Trp Thr Val Arg Ser Ile

1 5 10 15

His Asp Leu Arg Phe

20

(4) INFORMATION FOR SEQ ID NO: 4:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: protein

(ix) FEATURE:

(A) NAME: (Gln167Tyr) hCNTF

(B) OTHER INFORMATION: (Gln167Tyr) hCNTF sequence
from position 159 to position 178

(5) INFORMATION FOR SEQ ID NO: 5:

(A) LENGTH: 20 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: protein

(A) NAME: (Ser166Asp/Gln167His) hCNTF

(B) OTHER INFORMATION: (Ser166Asp/Gln167His) hCNTF

sequence from position 159 to position 178

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

(6) INFORMATION FOR SEQ ID NO: 6:

(A) LENGTH: 20 amino acids

(A) LENGTH: 20 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: protein

(A) NAME: (Gln163Ser/Gln167His) hCNTF

(B) OTHER INFORMATION: (Gln163Ser/Gln167His) hCNTF

sequence from position 159 to position 178

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

BNSDOCID: <WO 9822128A1_I_>

(A) LENGTH: 20 amino acids

- (ii) MOLECULE TYPE: protein

(A) NAME: (Gln167Ala) hCNTF

(B) ALTRE INFORMAZIONI: (Gln167Ala) hCNTF sequence

from position 159 to position 178

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

Leu Lys Val Leu Gln Glu Leu Ser Ala Trp Thr Val Arg Ser Ile

1 5 10 15

His Asp Leu Arg Phe

20

(8) INFORMATION FOR SEQ ID NO: 8:

(A) LENGHT: 20 amino acids

- (B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: unknown

(ix) FEATURE:

(A) NAME:: (Ser166Ala/Gln167Ala) hCNTF

(B) OTHER INFORMATION: (Ser166Ala/Gln167Ala) hCNTF

sequence from position 159 to position 178

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

Leu Lys Val Leu Gln Glu Leu Ala Ala Trp Thr Val Arg Ser Ile'

1 5 10 15

His Asp Leu Arg Phe

20

(9) INFORMATION FOR SEQ ID NO: 9:

(A) LENGTH: 20 amino acids

- (B) TYPE: amino acid
(C) STRANDEDNESS: single

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: protein

(ix) FEATURE:

(A) NAME: (Ser166Gly/Gln167Ala) hCNTF

(B) ALTRE INFORMAZIONI: (Ser166Gly/Gln167Ala) hCNTF
sequence from position 159 to position 178

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

Leu Lys Val Leu Gln Glu Leu Gly Ala Trp Thr Val Arg Ser Ile
1 5 10 15
His Asp Leu Arg Phe
20

(10) INFORMATION FOR SEQ ID NO: 10:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: protein

(ix) FEATURE:

(A) NAME: (Ser166Asn/Gln167Ala) hCNTF

(B) OTHER INFORMATION: (Ser166Asn/Gln167Ala) hCNTF
sequence from position 159 to position 178

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:

Leu Lys Val Leu Gln Glu Leu Asn Ala Trp Thr Val Arg Ser Ile
1 5 10 15
His Asp Leu Arg Phe
20

(11) INFORMATION FOR SEQ ID NO: 11:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: protein

(ix) FEATURE:

(A) NAME: (Ser166His/Gln167Ala) hCNTF

(B) OTHER INFORMATION: (Ser166His/Gln167Ala) hCNTF

sequence from position 159 to position 178

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:

Leu Lys Val Leu Gln Glu Leu His Ala Trp Thr Val Arg Ser Ile

1 5 10 15

His Asp Leu Arg Phe

20

(12) INFORMATION FOR SEQ ID NO: 12:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: protein

(ix) FEATURE:

(A) NAME: (Ser166Asp/Gln167Ala) hCNTF

(B) ALTRE INFORMAZIONI: (Ser166Asp/Gln167Ala) hCNTF

sequence from position 159 to position 178

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:

Leu Lys Val Leu Gln Glu Leu Asp Ala Trp Thr Val Arg Ser Ile

1 5 10 15

His Asp Leu Arg Phe

20

(13) INFORMATION FOR SEQ ID NO: 13:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: protein

(ix) FEATURE:

(A) NAME: (Val161Leu/Gln167Ala) hCNTF

(B) OTHER INFORMATION: (Val161Leu/Gln167Ala) hCNTF

sequence from position 159 to position 178

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:

Leu Lys Leu Leu Gln Glu Leu Ser Ala Trp Thr Val Arg Ser Ile

1 5 10 15

- 34 -

His Asp Leu Arg Phe

20

(14) INFORMATION FOR SEQ ID NO: 14:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: protein

(ix) FEATURE:

(A) NAME: (Lys160Gln/Gln167Ala) hCNTF

(B) OTHER INFORMATION: (Lys160Gln/Gln167Ala) hCNTF
sequence from position 159 to position 178

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14:

Leu Gln Val Leu Gln Glu Leu Ser Ala Trp Thr Val Arg Ser Ile

1 5 10 15

His Asp Leu Arg Phe

20

(15) INFORMATION FOR SEQ ID NO: 15:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: protein

(ix) FEATURE:

(A) NAME: (Gln167Ala/His174Ala) hCNTF

(B) OTHER INFORMATION: (Gln167Ala/His174Ala) hCNTF
sequence from position 159 to position 178

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15:

Leu Lys Val Leu Gln Glu Leu Ser Ala Trp Thr Val Arg Ser Ile

1 5 10 15

Ala Asp Leu Arg Phe

20

(16) INFORMATION FOR SEQ ID NO: 16:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 amino acids

(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: unknown
(ii) MOLECULE TYPE: protein
(ix) FEATURE:
 (A) NAME: (Gln167Ala/Arg177Leu) hCNTF
 (B) OTHER INFORMATION: (Gln167Ala/Arg177Leu) hCNTF
sequence from position 159 to position 178
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16:
Leu Lys Val Leu Gln Glu Leu Ser Ala Trp Thr Val Arg Ser Ile
1 5 10 15
His Asp Leu Leu Phe
20

(17) INFORMATION FOR SEQ ID NO: 17:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: protein

(ix) FEATURE:

(A) NAME: (Gln167Ala/Thr169Ser) hCNTF

(B) OTHER INFORMATION: (Gln167Ala/Thr169Ser) hCNTF
sequence from position 159 to position 178

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17:

```

Leu Lys Val Leu Gln Glu Leu Ser Ala Trp Ser Val Arg Ser Ile
1          5          10          15
His Asp Leu Arg Phe
          20

```

(18) INFORMATION FOR SEQ ID NO: 18:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: protein

(ix) FEATURE:

```
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18:
Leu Lys Val Leu Gln Glu Leu Ser Ala Trp Leu Val Arg Ser Ile
1          5          10          15
His Asp Leu Arg Phe
          20
```

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: protein

(ix) FEATURE:

(A) NAME: (Gln167Ala/Thr169Leu/Phe178Ile) hCNTF

(B) OTHER INFORMATION: (Gln167Ala/Thr169Leu/Phe178Ile)

hCNTF sequence from position 159 to position 178

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19:

```

Leu Lys Val Leu Gln Glu Leu Ser Ala Trp Leu Val Arg Ser Ile
1          5          10          15
His Asp Leu Arg Ile
          20

```

(20) INFORMATION FOR SEQ ID NO: 20:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: protein

(ix) FEATURE:

(A) NAME: (Ser166Asp/Gln167Ala/Thr169Leu) hCNTF

(B) OTHER INFORMATION: (Ser166Asp/Gln167Ala/Thr169Leu)

hCNTF sequence from position 159 to position 178

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20:

- 37 -

Leu Lys Val Leu Gln Glu Leu Asp Ala Trp Leu Val Arg Ser Ile .
1 5 10 15
His Asp Leu Arg Phe
 20

(21) INFORMATION FOR SEQ ID NO: 21:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: protein

(ix) FEATURE:

- (A) NAME: (Ser166Asp/Gln167Ala/Arg177Phe) hCNTF
- (B) OTHER INFORMATION: (Ser166Asp/Gln167Ala/Arg177Phe)

hCNTF sequence from position 159 to position 178

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21:

Leu Lys Val Leu Gln Glu Leu Asp Ala Trp Thr Val Arg Ser Ile
1 5 10 15
His Asp Leu Phe Phe
 20

(22) INFORMATION FOR SEQ ID NO: 22:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: protein

(ix) FEATURE:

- (A) NAME: (Val170Arg/His174Ala) hCNTF
- (B) OTHER INFORMATION: (Val170Arg/His174Ala) hCNTF

sequence from position 159 to position 178

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22:

Leu Lys Val Leu Gln Glu Leu Ser Gln Trp Thr Arg Arg Ser Ile
1 5 10 15
Ala Asp Leu Arg Phe
 20

(23) INFORMATION FOR SEQ ID NO: 23:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 200 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: protein

(ix) FEATURE:

(A) NAME: (Phe152Ala/Ser166Asp/Gln167His) hCNTF

(B) OTHER INFORMATION: (Phe152Ala/Ser166Asp/Gln167His)

hCNTF sequence from position 1 to position 200

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 23:

Met	Ala	Phe	Thr	Glu	His	Ser	Pro	Leu	Thr	Pro	His	Arg	Arg	Asp	1	5	10	15
Leu	Cys	Ser	Arg	Ser	Ile	Trp	Leu	Ala	Arg	Lys	Ile	Arg	Ser	Asp	20	25	30	
Leu	Thr	Ala	Leu	Thr	Glu	Ser	Tyr	Val	Lys	His	Gln	Gly	Leu	Asn	35	40	45	
Lys	Asn	Ile	Asn	Leu	Asp	Ser	Ala	Asp	Gly	Met	Pro	Val	Ala	Ser	50	55	60	
Thr	Asp	Gln	Trp	Ser	Glu	Leu	Thr	Glu	Ala	Glu	Arg	Leu	Gln	Glu	65	70	75	
Asn	Leu	Gln	Ala	Tyr	Arg	Thr	Phe	His	Val	Leu	Leu	Ala	Arg	Leu	80	85	90	
Leu	Glu	Asp	Gln	Gln	Val	His	Phe	Thr	Pro	Thr	Glu	Gly	Asp	Phe	95	100	105	
His	Gln	Ala	Ile	His	Thr	Leu	Leu	Leu	Gln	Val	Ala	Ala	Phe	Ala	110	115	120	
Tyr	Gln	Ile	Glu	Glu	Leu	Met	Ile	Leu	Leu	Glu	Tyr	Lys	Ile	Pro	125	130	135	
Arg	Asn	Glu	Ala	Asp	Gly	Met	Pro	Ile	Asn	Val	Gly	Asp	Gly	Gly	140	145	150	
Leu	Ala	Glu	Lys	Lys	Leu	Trp	Gly	Leu	Gln	Val	Leu	Gln	Glu	Leu	155	160	165	
Asp	His	Trp	Thr	Val	Arg	Ser	Ile	His	Asp	Leu	Arg	Phe	Ile	Ser	170	175	180	
Ser	His	Thr	Thr	Gly	Ile	Pro	Ala	Arg	Gly	Ser	His	Tyr	Ile	Ala	185	190	195	

Asn Asn Lys Lys Met

200

(24) INFORMATION FOR SEQ ID NO: 24:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 200 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: protein

(ix) FEATURE:

(A) NAME: (Lys155Ala/Ser166Asp/Gln167His) hCNTF

(B) OTHER INFORMATION: (Lys155Ala/Ser166Asp/Gln167His)

hCNTF sequence from position 1 to position 200

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 24:

Met	Ala	Phe	Thr	Glu	His	Ser	Pro	Leu	Thr	Pro	His	Arg	Arg	Asp
1				5					10					15
Leu	Cys	Ser	Arg	Ser	Ile	Trp	Leu	Ala	Arg	Lys	Ile	Arg	Ser	Asp
				20					25					30
Leu	Thr	Ala	Leu	Thr	Glu	Ser	Tyr	Val	Lys	His	Gln	Gly	Leu	Asn
				35					40					45
Lys	Asn	Ile	Asn	Leu	Asp	Ser	Ala	Asp	Gly	Met	Pro	Val	Ala	Ser
				50					55					60
Thr	Asp	Gln	Trp	Ser	Glu	Leu	Thr	Glu	Ala	Glu	Arg	Leu	Gln	Glu
				65					70					75
Asn	Leu	Gln	Ala	Tyr	Arg	Thr	Phe	His	Val	Leu	Leu	Ala	Arg	Leu
				80					85					90
Leu	Glu	Asp	Gln	Gln	Val	His	Phe	Thr	Pro	Thr	Glu	Gly	Asp	Phe
				95					100					105
His	Gln	Ala	Ile	His	Thr	Leu	Leu	Leu	Gln	Val	Ala	Ala	Phe	Ala
				110					115					120
Tyr	Gln	Ile	Glu	Glu	Leu	Met	Ile	Leu	Leu	Glu	Tyr	Lys	Ile	Pro
				125					130					135
Arg	Asn	Glu	Ala	Asp	Gly	Met	Pro	Ile	Asn	Val	Gly	Asp	Gly	Gly
				140					145					150
Leu	Phe	Glu	Lys	Ala	Leu	Trp	Gly	Leu	Lys	Val	Leu	Gln	Glu	Leu
				155					160					165

- 40 -

Asp His Trp Thr Val Arg Ser Ile His Asp Leu Arg Phe Ile Ser
 170 175 180
 Ser His Gln Thr Gly Ile Pro Ala Arg Gly Ser His Tyr Ile Ala
 185 190 195
 Asn Asn Lys Lys Met
 200

(25) INFORMATION FOR SEQ ID NO: 25:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 200 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: protein

(ix) FEATURE:

(A) NAME: (Q63R) hCNTF

(B) OTHER INFORMATION: (Q63R) hCNTF sequence from position 1 to position 200

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 25:

Met Ala Phe Thr Glu His Ser Pro Leu Thr Pro His Arg Arg Asp
 1 5 10 15
 Leu Cys Ser Arg Ser Ile Trp Leu Ala Arg Lys Ile Arg Ser Asp
 20 25 30
 Leu Thr Ala Leu Thr Glu Ser Tyr Val Lys His Gln Gly Leu Asn
 35 40 45
 Lys Asn Ile Asn Leu Asp Ser Ala Asp Gly Met Pro Val Ala Ser
 50 55 60
 Thr Asp Arg Trp Ser Glu Leu Thr Glu Ala Glu Arg Leu Gln Glu
 65 70 75
 Asn Leu Gln Ala Tyr Arg Thr Phe His Val Leu Leu Ala Arg Leu
 80 85 90
 Leu Glu Asp Gln Gln Val His Phe Thr Pro Thr Glu Gly Asp Phe
 95 100 105
 His Gln Ala Ile His Thr Leu Leu Leu Gln Val Ala Ala Phe Ala
 110 115 120
 Tyr Gln Ile Glu Glu Leu Met Ile Leu Leu Glu Tyr Lys Ile Pro
 125 130 135

- 41 -

```

Arg Asn Glu Ala Asp Gly Met Pro Ile Asn Val Gly Asp Gly Gly
      140                      145                      150
Leu Phe Glu Lys Lys Leu Trp Gly Leu Lys Val Leu Gln Glu Leu
      155                      160                      165
Ser Gln Trp Thr Val Arg Ser Ile His Asp Leu Arg Phe Ile Ser
      170                      175                      180
Ser His Gln Thr Gly Ile Pro Ala Arg Gly Ser His Tyr Ile Ala
      185                      190                      195
Asn Asn Lys Lys Met
      200

```

(26) INFORMATION FOR SEQ ID NO: 26:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 200 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: protein

(ix) FEATURE:

(A) NAME: (Gln63Arg/Ser166Asp/Gln167His) hCNTF

(B) OTHER INFORMATION: (Gln63Arg/Ser166Asp/Gln167His)

hCNTF sequence from position 1 to position 200

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 26

```

Met Ala Phe Thr Glu His Ser Pro Leu Thr Pro His Arg Arg Asp
1           5           10           15
Leu Cys Ser Arg Ser Ile Trp Leu Ala Arg Lys Ile Arg Ser Asp
      20           25           30
Leu Thr Ala Leu Thr Glu Ser Tyr Val Lys His Gln Gly Leu Asn
      35           40           45
Lys Asn Ile Asn Leu Asp Ser Ala Asp Gly Met Pro Val Ala Ser
      50           55           60
Thr Asp Arg Trp Ser Glu Leu Thr Glu Ala Glu Arg Leu Gln Glu
      65           70           75
Asn Leu Gln Ala Tyr Arg Thr Phe His Val Leu Leu Ala Arg Leu
      80           85           90
Leu Glu Asp Gln Gln Val His Phe Thr Pro Thr Glu Gly Asp Phe
      95          100          105

```

Met	Ala	Phe	Thr	Glu	His	Ser	Pro	Leu	Thr	Pro	His	Arg	Arg	Asp
1				5					10					15
Leu	Cys	Ser	Arg	Ser	Ile	Trp	Leu	Ala	Arg	Lys	Ile	Arg	Ser	Gln
				20					25					30
Leu	Thr	Ala	Leu	Thr	Glu	Ser	Tyr	Val	Lys	His	Gln	Gly	Leu	Asn
				35					40					45
Lys	Asn	Ile	Asn	Leu	Asp	Ser	Ala	Asp	Gly	Met	Pro	Val	Ala	Ser
				50					55					60
Thr	Asp	Gln	Trp	Ser	Glu	Leu	Thr	Glu	Ala	Glu	Arg	Leu	Gln	Glu
				65					70					75

```

Asn Leu Gln Ala Tyr Arg Thr Phe His Val Leu Leu Ala Arg Leu
      80                      85                      90
Leu Glu Asp Gln Gln Val His Phe Thr Pro Thr Glu Gly Asp Phe
      95                      100                     105
His Gln Ala Ile His Thr Leu Leu Leu Gln Val Ala Ala Phe Ala
      110                     115                     120
Tyr Gln Ile Glu Glu Leu Met Ile Leu Leu Glu Tyr Lys Ile Pro
      125                     130                     135
Arg Asn Glu Ala Asp Gly Met Pro Ile Asn Val Gly Asp Gly Gly
      140                     145                     150
Leu Phe Glu Lys Lys Leu Trp Gly Leu Lys Val Leu Gln Glu Leu
      155                     160                     165
Asp His Trp Thr Val Arg Ser Ile His Asp Leu Arg Phe Ile Ser
      170                     175                     180
Ser His Gln Thr Gly Ile Pro Ala Arg Gly Ser His Tyr Ile Ala
      185                     190                     195
Asn Asn Lys Lys Met
      200

```

(28) INFORMATION FOR SEQ ID NO: 28:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 200 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: protein

(ix) FEATURE:

(A) NAME: (Thr169Ile/His174Ala) hCNTF

(B) OTHER INFORMATION: (Thr169Ile/His174Ala) hCNTF
sequence from position 1 to position 200

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 28:

```

Met Ala Phe Thr Glu His Ser Pro Leu Thr Pro His Arg Arg Asp
1          5          10          15
Leu Cys Ser Arg Ser Ile Trp Leu Ala Arg Lys Ile Arg Ser Asp
      20          25          30
Leu Thr Ala Leu Thr Glu Ser Tyr Val Lys His Gln Gly Leu Asn
      35          40          45

```

Lys	Asn	Ile	Asn	Leu	Asp	Ser	Ala	Asp	Gly	Met	Pro	Val	Ala	Ser
			50						55				60	
Thr	Asp	Gln	Trp	Ser	Glu	Leu	Thr	Glu	Ala	Glu	Arg	Leu	Gln	Glu
			65						70				75	
Asn	Leu	Gln	Ala	Tyr	Arg	Thr	Phe	His	Val	Leu	Leu	Ala	Arg	Leu
			80						85				90	
Leu	Glu	Asp	Gln	Gln	Val	His	Phe	Thr	Pro	Thr	Glu	Gly	Asp	Phe
			95						100				105	
His	Gln	Ala	Ile	His	Thr	Leu	Leu	Leu	Gln	Val	Ala	Ala	Phe	Ala
			110						115				120	
Tyr	Gln	Ile	Glu	Glu	Leu	Met	Ile	Leu	Leu	Glu	Tyr	Lys	Ile	Pro
			125						130				135	
Arg	Asn	Glu	Ala	Asp	Gly	Met	Pro	Ile	Asn	Val	Gly	Asp	Gly	Gly
			140						145				150	
Leu	Phe	Glu	Lys	Lys	Leu	Trp	Gly	Leu	Lys	Val	Leu	Gln	Glu	Leu
			155						160				165	
Ser	Gln	Trp	Ile	Val	Arg	Ser	Ile	Ala	Asp	Leu	Arg	Phe	Ile	Ser
			170						175				180	
Ser	His	Gln	Thr	Gly	Ile	Pro	Ala	Arg	Gly	Ser	His	Tyr	Ile	Ala
			185						190				195	
Asn	Asn	Lys	Lys	Met										
			200											

CLAIMS

1. Use of substances that activate the CNTF (ciliary neurotrophic factor) receptor for the preparation of pharmaceutical compositions for the treatment of obesity and diseases associated therewith, for example diabetes.

2. Use of substances that activate the CNTF receptor according to claim 1, in which the substances that activate the CNTF receptor are hCNTF (human ciliary neurotrophic factor) or a mutant thereof.

3. Use of substances that activate the CNTF receptor according to claim 2, in which the mutant of hCNTF is selected from the group comprising SEQ ID NO:2 to SEQ ID NO:28.

4. Use of substances that activate the CNTF receptor according to claim 3, in which the mutant of hCNTF is SEQ ID NO:5.

5. Use of DNA coding for hCNTF or mutants thereof for the preparation of compositions for the gene-therapy of obesity and diseases associated therewith.

6. Pharmaceutical composition for the treatment of obesity and diseases associated therewith, comprising a pharmaceutically acceptable vehicle, characterised in that it contains as at least one of the active principles hCNTF or at least one of its mutant forms, selected from the group comprising SEQ ID NO:2 to SEQ ID NO:28.

7. Pharmaceutical composition according to claim 6, in which the active principles are hCNTF, or one of its mutant forms, and leptin, the ratio wild type or mutant CNTF/leptin being 1:500 to 1:5.

8. Pharmaceutical composition according to claim 7, in which the ratio wild type or mutant CNTF/leptin is 1:100 to 1:25.

9. Pharmaceutical compositions according to claims from 5 to 8, formulated for parenteral, nasal, bronchial, transdermal or rectal administration.


10. Method of administration for the pharmaceutical compositions according to claims 5 to 9, characterised in

that the active principles is administered in daily doses of between 1 and 10,000 µg/kg body weight.

11. Method of administration according to claim 10, in which the daily doses are preferably between 10 and 5 1000 µg/kg body weight.


- 1/7 -

FIG. 1




- 2/7 -

FIG. 2




- 3/7 -

FIG. 3



- 4/7 -


FIG. 4



Effect of vehicle (□) or DH-CNTF (■) treatment
on carcass composition of obese mice


- 5/7 -

FIG. 5




- 6/7 -

FIG. 6



- 7/7 -

FIG. 7



INTERNATIONAL SEARCH REPORT

International Application No

PCT/IT 97/00283

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K38/18 A61K48/00 //(A61K38/18,38:22)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>A. DI MARCO ET AL.: "Identification of ciliary neurotrophic (CNTF) residues essential for leukemia inhibitor factor receptor binding and generation of CNTF receptor antagonists"</p> <p>PROC. NATL. ACAD. SCI. USA, vol. 93, August 1996, pages 9247-9252, XP002056938</p> <p>see the whole document</p> <p>---</p> <p>-/--</p>	1-11

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

9 March 1998

Date of mailing of the international search report

26. 03. 1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Moreau, J

INTERNATIONAL SEARCH REPORT

Intern 1al Application No

PCT/IT 97/00283

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	I. SAGGIO ET AL: "CNTF variants with increased biological potency and receptor selectivity defin a functional site of receptor interaction" EMBO J., vol. 14, no. 13, 1995, pages 3045-3054, XP002056939 see the whole document see tables 1,2	1-11
A	--- FANTUZZI G ET AL: "Ciliary neurotrophic factor (CNTF) induces serum amyloid A, hypoglycaemia and anorexia, and potentiates IL-1 induced corticosterone and IL-6 production in mice." CYTOKINE, vol. 7, no. 2, February 1995, pages 150-156, XP002058096 cited in the application see the whole document	1-11
P,X	--- SARRAF P ET AL: "Multiple cytokines and acute inflammation raise mouse leptin levels: Potential role in inflammatory anorexia." JOURNAL OF EXPERIMENTAL MEDICINE 185 (1). 1997. 171-175, XP002058097 see the whole document	1-11
P,X	--- GLOAGUEN I ET AL: "Ciliary neurotrophic factor corrects obesity and diabetes associated with leptin deficiency and resistance." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 94 (12). 1997. 6456-6461, XP002058098 see the whole document	1-11
E	--- WO 98 01149 A (ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELLTI) 15 January 1998 see the whole document -----	1-11

INTERNATIONAL SEARCH REPORT

International application No.
PCT/IT 97/00283

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Remark : Although claims 10-11 are directed to a method of treatment of the human/animal body , the search has been carried out and based on the alleged effects of the compound/composition.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Internal Application No

PCT/IT 97/00283

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9801149 A	15-01-98	NONE	